The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Krystal Biotech P/E ratio is -18.09. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Krystal Biotech’s P/E ratio
What is Krystal Biotech P/E Ratio?
Krystal Biotech’s P/E ratio is 18.09, which represents a 21.59% increase over the same period last year. their average P / E ratio is -17.19 and their 5-year average is -22.42.
What is Krystal Biotech Net EPS?
Krystal Biotech’s net earnings for the last quarter were -4.13$, which represents a 65.2% decrease from the same period last year.
Who are Krystal Biotech Competitors?
Based on Jika.io AI model, Editas Medicine, Iovance Biotherapeutics, Kodiak Sciences, Lexicon Pharmaceuticals, Seres Therapeutics, Mersana Therapeutics, Nurix Therapeutics, uniQure N.V. are considered to be Krystal Biotech’s competitors because the companies operate within the same industry as Krystal Biotech and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Krystal Biotech.
Who is Krystal Biotech’s Biggest competitor?
Krystal Biotech’s biggest competitor is Editas Medicine based on the Jika.io AI model. it has a similar market capitalization to Krystal Biotech within the industry, it dominates a similar share of the market as Krystal Biotech, and it provides and markets very similar services.
What industry is Krystal Biotech in?
Krystal Biotech is part of the biotechnology industry and the healthcare sector.
Krystal Biotech vs Editas Medicine
Market Cap: Krystal Biotech’s Market Cap of 1915711104 is higher than Editas Medicine Market Cap of 984313472.
Average Volume: Krystal Biotech’s Average Volume of 182158.0 is higher than Editas Medicine Average Volume of 1.726M.
Beta: Krystal Biotech’s Beta of 0.99 is lower than Editas Medicine Beta of 2.06.
Revenue: Krystal Biotech’s Revenue of 0.0 is lower than Editas Medicine Revenue of 25.544M.
Net Income: Krystal Biotech’s Net Income of -69.57M is higher than Editas Medicine Net Income of -192.502M.
Gross Profit: Krystal Biotech’s Gross Profit of 0.0 is lower than Editas Medicine Gross Profit of 0.0.
Ebitda: Krystal Biotech’s Ebitda of -65.309M is higher than Editas Medicine Ebitda of -187.449M.
P/E Ratio: Krystal Biotech’s P/E Ratio of -18.09 is lower than Editas Medicine P/E Ratio of -5.27.
P/B Ratio: Krystal Biotech’s P/B Ratio of 3.42 is higher than Editas Medicine P/B Ratio of 1.92.
P/FCF Ratio: Krystal Biotech’s P/FCF Ratio of -13.72 is lower than Editas Medicine P/FCF Ratio of -5.65.
ROE: Krystal Biotech’s ROE of -0.21 is lower than Editas Medicine ROE of -0.33.
ROA: Krystal Biotech’s ROA of -0.17 is lower than Editas Medicine ROA of -0.3.
Return On Capital Employed: Krystal Biotech’s Return On Capital Employed of -0.19 is lower than Editas Medicine Return On Capital Employed of -0.32.
Assets (Total): Krystal Biotech’s Assets (Total) of 626.295M is lower than Editas Medicine Assets (Total) of 677.483M.
Debt (Total): Krystal Biotech’s Debt (Total) of 8.024M is higher than Editas Medicine Debt (Total) of 26.378M.
Shareholders Equity: Krystal Biotech’s Shareholders Equity of 593.576M is higher than Editas Medicine Shareholders Equity of 553.642M.
Krystal Biotech vs Iovance Biotherapeutics
Market Cap: Krystal Biotech’s Market Cap of 1915711104 is higher than Iovance Biotherapeutics Market Cap of 1884444288.
Average Volume: Krystal Biotech’s Average Volume of 182158.0 is lower than Iovance Biotherapeutics Average Volume of 5.025M.
Beta: Krystal Biotech’s Beta of 0.99 is higher than Iovance Biotherapeutics Beta of 0.91.
Revenue: Krystal Biotech’s Revenue of 0.0 is lower than Iovance Biotherapeutics Revenue of 0.0.
Net Income: Krystal Biotech’s Net Income of -69.57M is higher than Iovance Biotherapeutics Net Income of -342.252M.
Gross Profit: Krystal Biotech’s Gross Profit of 0.0 is lower than Iovance Biotherapeutics Gross Profit of 0.0.
Ebitda: Krystal Biotech’s Ebitda of -65.309M is higher than Iovance Biotherapeutics Ebitda of -342.703M.
P/E Ratio: Krystal Biotech’s P/E Ratio of -18.09 is lower than Iovance Biotherapeutics P/E Ratio of -5.26.
P/B Ratio: Krystal Biotech’s P/B Ratio of 3.42 is higher than Iovance Biotherapeutics P/B Ratio of 3.41.
P/FCF Ratio: Krystal Biotech’s P/FCF Ratio of -13.72 is lower than Iovance Biotherapeutics P/FCF Ratio of -6.78.
ROE: Krystal Biotech’s ROE of -0.21 is lower than Iovance Biotherapeutics ROE of -0.55.
ROA: Krystal Biotech’s ROA of -0.17 is lower than Iovance Biotherapeutics ROA of -0.51.
Return On Capital Employed: Krystal Biotech’s Return On Capital Employed of -0.19 is lower than Iovance Biotherapeutics Return On Capital Employed of -0.57.
Assets (Total): Krystal Biotech’s Assets (Total) of 626.295M is lower than Iovance Biotherapeutics Assets (Total) of 777.333M.
Debt (Total): Krystal Biotech’s Debt (Total) of 8.024M is higher than Iovance Biotherapeutics Debt (Total) of 141.062M.
Shareholders Equity: Krystal Biotech’s Shareholders Equity of 593.576M is lower than Iovance Biotherapeutics Shareholders Equity of 621.659M.
Krystal Biotech vs Kodiak Sciences
Market Cap: Krystal Biotech’s Market Cap of 1915711104 is higher than Kodiak Sciences Market Cap of 423421824.
Average Volume: Krystal Biotech’s Average Volume of 182158.0 is lower than Kodiak Sciences Average Volume of 936703.0.
Beta: Krystal Biotech’s Beta of 0.99 is lower than Kodiak Sciences Beta of 1.96.
Revenue: Krystal Biotech’s Revenue of 0.0 is lower than Kodiak Sciences Revenue of 0.0.
Net Income: Krystal Biotech’s Net Income of -69.57M is higher than Kodiak Sciences Net Income of -266.99M.
Gross Profit: Krystal Biotech’s Gross Profit of 0.0 is lower than Kodiak Sciences Gross Profit of 0.0.
Ebitda: Krystal Biotech’s Ebitda of -65.309M is higher than Kodiak Sciences Ebitda of -258.257M.
P/E Ratio: Krystal Biotech’s P/E Ratio of -18.09 is higher than Kodiak Sciences P/E Ratio of -1.36.
P/B Ratio: Krystal Biotech’s P/B Ratio of 3.42 is higher than Kodiak Sciences P/B Ratio of 0.71.
P/FCF Ratio: Krystal Biotech’s P/FCF Ratio of -13.72 is higher than Kodiak Sciences P/FCF Ratio of -1.6.
ROE: Krystal Biotech’s ROE of -0.21 is lower than Kodiak Sciences ROE of -0.45.
ROA: Krystal Biotech’s ROA of -0.17 is lower than Kodiak Sciences ROA of -0.37.
Return On Capital Employed: Krystal Biotech’s Return On Capital Employed of -0.19 is lower than Kodiak Sciences Return On Capital Employed of -0.4.
Assets (Total): Krystal Biotech’s Assets (Total) of 626.295M is lower than Kodiak Sciences Assets (Total) of 904.22M.
Debt (Total): Krystal Biotech’s Debt (Total) of 8.024M is higher than Kodiak Sciences Debt (Total) of 79.996M.
Shareholders Equity: Krystal Biotech’s Shareholders Equity of 593.576M is lower than Kodiak Sciences Shareholders Equity of 663.32M.
Krystal Biotech vs Lexicon Pharmaceuticals
Market Cap: Krystal Biotech’s Market Cap of 1915711104 is higher than Lexicon Pharmaceuticals Market Cap of 393432224.
Average Volume: Krystal Biotech’s Average Volume of 182158.0 is higher than Lexicon Pharmaceuticals Average Volume of 1.148M.
Beta: Krystal Biotech’s Beta of 0.99 is lower than Lexicon Pharmaceuticals Beta of 1.53.
Revenue: Krystal Biotech’s Revenue of 0.0 is lower than Lexicon Pharmaceuticals Revenue of 298000.0.
Net Income: Krystal Biotech’s Net Income of -69.57M is lower than Lexicon Pharmaceuticals Net Income of -87.758M.
Gross Profit: Krystal Biotech’s Gross Profit of 0.0 is lower than Lexicon Pharmaceuticals Gross Profit of 298000.0.
Ebitda: Krystal Biotech’s Ebitda of -65.309M is lower than Lexicon Pharmaceuticals Ebitda of -86.956M.
P/E Ratio: Krystal Biotech’s P/E Ratio of -18.09 is lower than Lexicon Pharmaceuticals P/E Ratio of -4.35.
P/B Ratio: Krystal Biotech’s P/B Ratio of 3.42 is lower than Lexicon Pharmaceuticals P/B Ratio of 4.23.
P/FCF Ratio: Krystal Biotech’s P/FCF Ratio of -13.72 is lower than Lexicon Pharmaceuticals P/FCF Ratio of -6.16.
ROE: Krystal Biotech’s ROE of -0.21 is lower than Lexicon Pharmaceuticals ROE of 0.32.
ROA: Krystal Biotech’s ROA of -0.17 is lower than Lexicon Pharmaceuticals ROA of -0.66.
Return On Capital Employed: Krystal Biotech’s Return On Capital Employed of -0.19 is lower than Lexicon Pharmaceuticals Return On Capital Employed of -0.76.
Assets (Total): Krystal Biotech’s Assets (Total) of 626.295M is higher than Lexicon Pharmaceuticals Assets (Total) of 136.909M.
Debt (Total): Krystal Biotech’s Debt (Total) of 8.024M is higher than Lexicon Pharmaceuticals Debt (Total) of 0.0.
Shareholders Equity: Krystal Biotech’s Shareholders Equity of 593.576M is higher than Lexicon Pharmaceuticals Shareholders Equity of -1.488B.
About Krystal Biotech
Krystal Biotech, Inc., a clinical biotechnology company, is engaged in the field of redosable gene therapy for the treatment of serious rare diseases in the United States. its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study for the treatment of dystrophic epidermolysis bullosa. the company is also involved in developing KB105, which is in phase I / II clinical study for the treatment of patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in phase I / II clinical study for the treatment of wrinkles and other signs of aged or damaged skin; KB407, which is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. its product candidates for the discovery stage include KB5xx for chronic skin diseases, KB3xx for aesthetic skin conditions and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
